Highly multiplexed digital PCR assay for simultaneous quantification of variant allele frequencies and copy number alterations of KRAS and GNAS in pancreatic cancer precursors
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Junko Tanaka und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Digital Services - Healthcare, Research & Development Group, Hitachi, Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Chromogranins, GTP-Binding Protein alpha Subunits, Gs, Proto-Oncogene Proteins p21(ras), Pancreatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hitachi, Ltd., Japan Society for the Promotion of Science, Hitachi.
Abstract (Originalsprache)
Pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasms (IPMNs) are pancreatic ductal adenocarcinoma (PDAC) precursor lesions. Detecting these precursors and monitoring their progression are crucial for early PDAC diagnosis. Digital PCR (dPCR) is a highly sensitive nucleic acid quantification technique and offers a cost‐effective option for patient follow‐up. However, the clinical utility of conventional dPCR is restricted by multiplexing constraints, particularly due to the challenge of simultaneously quantifying multiple mutations and amplifications. In this study, we applied highly multiplexed dPCR and melting curve analysis to simultaneously measure single nucleotide mutations and amplifications of KRAS and GNAS . The developed 14‐plex assay included both wild‐type and mutant KRAS , a common driver gene in both PanIN and IPMN, and GNAS , which is specifically mutated in IPMN, along with RPP30 , a reference gene for copy number alterations (CNAs). This multiplex dPCR method detected all target mutations with a limit of detection below 0.2% while quantifying CNAs. Additionally, the assay accurately quantified variant allele frequencies in liquid biopsy and tissue samples from both pancreatic neoplasm precursor and PDAC patients, indicating its potential for use in comprehensive patient follow‐up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Digital Services - Healthcare, Research & Development Group, Hitachi, Ltd., Tokyo, Japan.
- Institute of Biomedical Research, Sapporo Higashi Tokushukai Hospital, Japan.
- Department of Advanced Genomic Community Healthcare, Asahikawa Medical University, Japan.
- Division of Gastroenterology, Department of Medicine, Asahikawa Medical University, Japan.
- Division of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
ORCID-Profile: Junko Tanaka, Kenji Takahashi, Andrew S Liss, Yusuke Mizukami
Förderung
- Hitachi, Ltd.
- Japan Society for the Promotion of Science
- Hitachi
Zitieren
APA
Tanaka, J., Nakagawa, T., Ono, Y., Kamura, Y., Ishida, T., Kawabata, H., Takahashi, K., Sato, H., Liss, A. S., Mizukami, Y., & Yokoi, T. (2025). Highly multiplexed digital PCR assay for simultaneous quantification of variant allele frequencies and copy number alterations of KRAS and GNAS in pancreatic cancer precursors. Molecular Oncology. https://doi.org/10.1002/1878-0261.70011
Vancouver
Tanaka J, Nakagawa T, Ono Y, Kamura Y, Ishida T, Kawabata H, et al. Highly multiplexed digital PCR assay for simultaneous quantification of variant allele frequencies and copy number alterations of KRAS and GNAS in pancreatic cancer precursors. Molecular Oncology. 2025. doi:10.1002/1878-0261.70011
BibTeX
@article{Tanaka2025,
author = {Tanaka, Junko and Nakagawa, Tatsuo and Ono, Yusuke and Kamura, Yoshio and Ishida, Takeshi and Kawabata, Hidemasa and Takahashi, Kenji and Sato, Hiroki and Liss, Andrew S and Mizukami, Yusuke and Yokoi, Takahide},
title = {Highly multiplexed digital PCR assay for simultaneous quantification of variant allele frequencies and copy number alterations of KRAS and GNAS in pancreatic cancer precursors},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70011}
}
EUVIMED